Switches of migraine, nail fungus treatments may be next FDA challenges, Juhl predicts.
This article was originally published in The Tan Sheet
Executive Summary
RX-TO-OTC SWITCH OF MIGRAINE, NAIL FUNGAL INFECTION TREATMENTS may represent the next challenges for FDA in the area of switches, former Nonprescription Drugs Advisory Committee Chair Randy Juhl, PhD, University of Pittsburgh School of Pharmacy, suggested at a May 29 FDA meeting in Bethesda, Md. The meeting was convened by FDA's Office of Health Affairs to apprise health professional organizations about the Rx-to-OTC switch process and the agency's recent OTC labeling proposal.